Developer docs
API playgroundTry for free, no card

Search company profiles

Follica

Full company profile

uuid0007ds9

Namestring
Follica
Legal namestring
Follica, Inc.
Websiteurl
follicabio.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Follica, Inc. is a Boston-based, privately held regenerative medicine platform company developing proprietary hair growth therapies for individuals suffering from hair loss and alopecia. The company's core technology is a "Skin Disruption" approach, a novel method architecture designed to stimulate regenerative hair follicle responses, positioning it as a non-pharmaceutical alternative to drug-based interventions such as JAK inhibitors (e.g., Pfizer's LITFULO). The platform is structured to support both at-home self-administered use and an integrated clinician-delivered format, suggesting a dual commercial pathway once regulatory clearance is achieved.

Founded in 2005 and operating with a small team of 1-10 employees, Follica has raised approximately $24.1M across four disclosed funding rounds between 2008 and 2010, with Polaris Partners, PureTech Health, and InterWest Partners as the principal backers. The company's scientific founders include George Cotsarelis (a leading hair follicle stem cell researcher) and Rox Anderson (a Harvard/MGH dermatologist known for laser dermatology), with executive leadership drawn from the dermatology venture ecosystem, including Executive Chairman Neal Walker. The company is currently pre-commercial, with no disclosed revenue, no public pricing, and no announced regulatory filings; commercial inquiries are routed through a generic contact email rather than a transactional channel.

The go-to-market posture described in available materials is direct-to-consumer within a North American footprint, targeting a horizontal segment of individuals seeking regenerative hair growth treatments rather than enterprise or institutional buyers. There are no named customers, partnerships, distribution agreements, or product launches disclosed in the source data, and no capital has been publicly documented since late 2010, leaving the company's recent operating tempo, clinical progress, and capital structure ambiguous and dependent on direct management diligence.

Short descriptiontext

Follica is a Boston-based regenerative medicine platform company developing proprietary skin-disruption-based hair growth therapies for individuals with hair loss, differentiating itself from pharmaceutical approaches such as JAK inhibitors through a non-drug mechanism of action and dual at-home and integrated delivery formats.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative hair growth, hair loss treatment, skin disruption therapy, at-home hair care, hair follicle regeneration
Industry1 code
PRIMARYCRABABAE
Treatments & Scalp Care (Serums, Oils, Anti-dandruff, Growth)
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Perfumes, Cosmetics & Other Toilet Preparations2844
Product category
Regenerative Hair Loss Treatment
Social media profiles2 records
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Follica develops a regenerative platform technology for hair growth based on a proprietary skin disruption methodology designed to stimulate regenerative hair follicle responses. The company is building both at-home and integrated treatment approaches intended for individuals experiencing hair loss, alopecia, and related conditions, positioning its offering as a non-pharmaceutical alternative to drug-based hair loss therapies.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Follica is a regenerative platform company focused on hair growth treatments. The company operates from Boston, MA and is developing treatments centered on skin disruption technology for hair regeneration. The platform appears to offer both at-home and integrated approaches to treatment delivery.

Product and service2 records
1Regenerative Hair Growth Platform
CategoryRegenerative Hair Loss Treatment
Description

A regenerative platform treatment for hair growth based on proprietary skin disruption methodology, designed to stimulate regenerative hair follicle responses in individuals with hair loss, alopecia, and related conditions.

2At-Home Integrated Hair Growth Solution
CategoryAt-Home Hair Care Device
Description

An at-home treatment offering designed to deliver Follica's regenerative hair growth therapy directly to consumers in a home-use setting.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage regenerative medicine company developing novel hair growth treatments. Directly comparable to Follica as a biotech using a non-pharmaceutical, regenerative mechanism to treat hair loss.

TypeBroad incumbent
Description

Large pharmaceutical company with LITFOLO (JAK inhibitor), an approved alopecia areata therapy. Comparable as the dominant pharmaceutical incumbent competing in Follica's target indication.

TypeDirect peer
Description

Direct-to-consumer hair loss treatment brand offering finasteride and minoxidil. Comparable to Follica's at-home distribution model targeting the same consumer hair-loss segment.

TypeDirect peer
Description

Early-stage biotech engineering hair follicle growth via regenerative biology. Directly comparable to Follica's skin-disruption and regenerative approach to hair loss.

TypeDirect peer
Description

Clinical-stage dermatology company developing treatments for alopecia and other hair loss conditions. Comparable target indication and stage, with overlapping scientific focus on hair follicle biology.

6Johnson & Johnson
TypeBroad incumbent
Description

Consumer health incumbent through Rogaine (minoxidil) and other personal care brands. Comparable as the established consumer hair-growth incumbent Follica would compete against.

7Cassiopea
TypeEmerging player
Description

Dermatology-focused company that has developed clascoterone (Winlevi) and explored androgenetic alopecia indications. Comparable as a specialty dermatology player with hair-loss relevance.

TypeBroad incumbent
Description

Major pharma whose Olumiant (baricitinib) is approved for severe alopecia areata. Relevant incumbent competitor in the systemic-treatment segment of Follica's market.

TypeDirect peer
Description

Preclinical/early-clinical company developing iPSC-derived hair follicle regeneration. Closely comparable to Follica in pursuing a regenerative cell- and follicle-based approach to hair loss.

TypeEmerging player
Description

Digital health company offering hair loss treatments (including finasteride) directly to consumers. Comparable as a direct-to-consumer hair-loss brand, though broader in scope.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Follica

Regenerative Hair Loss Treatmentfollicabio.com

Follica is a Boston-based regenerative medicine platform company developing proprietary skin-disruption-based hair growth therapies for individuals with hair loss, differentiating itself from pharmaceutical approaches such as JAK inhibitors through a non-drug mechanism of action and dual at-home and integrated delivery formats.

What Follica does

Follica, Inc. is a Boston-based, privately held regenerative medicine platform company developing proprietary hair growth therapies for individuals suffering from hair loss and alopecia. The company's core technology is a "Skin Disruption" approach, a novel method architecture designed to stimulate regenerative hair follicle responses, positioning it as a non-pharmaceutical alternative to drug-based interventions such as JAK inhibitors (e.g., Pfizer's LITFULO). The platform is structured to support both at-home self-administered use and an integrated clinician-delivered format, suggesting a dual commercial pathway once regulatory clearance is achieved.

Founded in 2005 and operating with a small team of 1-10 employees, Follica has raised approximately $24.1M across four disclosed funding rounds between 2008 and 2010, with Polaris Partners, PureTech Health, and InterWest Partners as the principal backers. The company's scientific founders include George Cotsarelis (a leading hair follicle stem cell researcher) and Rox Anderson (a Harvard/MGH dermatologist known for laser dermatology), with executive leadership drawn from the dermatology venture ecosystem, including Executive Chairman Neal Walker. The company is currently pre-commercial, with no disclosed revenue, no public pricing, and no announced regulatory filings; commercial inquiries are routed through a generic contact email rather than a transactional channel.

The go-to-market posture described in available materials is direct-to-consumer within a North American footprint, targeting a horizontal segment of individuals seeking regenerative hair growth treatments rather than enterprise or institutional buyers. There are no named customers, partnerships, distribution agreements, or product launches disclosed in the source data, and no capital has been publicly documented since late 2010, leaving the company's recent operating tempo, clinical progress, and capital structure ambiguous and dependent on direct management diligence.

Follica firmographics

Firmographics
Name
Follica
Legal name
Follica, Inc.
Website
https://follicabio.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
1–10 employees
Short description
Follica is a Boston-based regenerative medicine platform company developing proprietary skin-disruption-based hair growth therapies for individuals with hair loss, differentiating itself from pharmaceutical approaches such as JAK inhibitors through a non-drug mechanism of action and dual at-home and integrated delivery formats.
Ownership category
akta.pro rank

Follica industry classification

Industry
Product category
Regenerative Hair Loss Treatment
NAICS
Medicinal and Botanical Manufacturing (325411)
SIC
Perfumes, Cosmetics & Other Toilet Preparations (2844)
akta.pro industry
PRIMARYCRABABAE
Treatments & Scalp Care (Serums, Oils, Anti-dandruff, Growth)

Keywords

  • Regenerative hair growth
  • Hair loss treatment
  • Skin disruption therapy
  • At-home hair care
  • Hair follicle regeneration

Where Follica is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Follica business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Distribution channels1 record

Marketing channels1 record

Follica product offering

Product offering

Core offering

Follica develops a regenerative platform technology for hair growth based on a proprietary skin disruption methodology designed to stimulate regenerative hair follicle responses. The company is building both at-home and integrated treatment approaches intended for individuals experiencing hair loss, alopecia, and related conditions, positioning its offering as a non-pharmaceutical alternative to drug-based hair loss therapies.

Product overview

Follica is a regenerative platform company focused on hair growth treatments. The company operates from Boston, MA and is developing treatments centered on skin disruption technology for hair regeneration. The platform appears to offer both at-home and integrated approaches to treatment delivery.

Differentiator

Problem solved

Functional benefit

Products and services

  • Regenerative Hair Growth Platform A regenerative platform treatment for hair growth based on proprietary skin disruption methodology, designed to stimulate regenerative hair follicle responses in individuals with hair loss, alopecia, and related conditions.
  • At-Home Integrated Hair Growth Solution An at-home treatment offering designed to deliver Follica's regenerative hair growth therapy directly to consumers in a home-use setting.

Companies that use Follica

Customer profile

Segments1 record

Ideal customer profiles1 record

Follica technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Follica partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights4 records

Follica competitors and assessment

Company assessment

Direct peers

  • Histogen: Clinical-stage regenerative medicine company developing novel hair growth treatments. Directly comparable to Follica as a biotech using a non-pharmaceutical, regenerative mechanism to treat hair loss.
  • Keeps: Direct-to-consumer hair loss treatment brand offering finasteride and minoxidil. Comparable to Follica's at-home distribution model targeting the same consumer hair-loss segment.
  • dNovo: Early-stage biotech engineering hair follicle growth via regenerative biology. Directly comparable to Follica's skin-disruption and regenerative approach to hair loss.
  • Aclaris Therapeutics: Clinical-stage dermatology company developing treatments for alopecia and other hair loss conditions. Comparable target indication and stage, with overlapping scientific focus on hair follicle biology.
  • Stemson Therapeutics: Preclinical/early-clinical company developing iPSC-derived hair follicle regeneration. Closely comparable to Follica in pursuing a regenerative cell- and follicle-based approach to hair loss.

Broad incumbents

  • Pfizer: Large pharmaceutical company with LITFOLO (JAK inhibitor), an approved alopecia areata therapy. Comparable as the dominant pharmaceutical incumbent competing in Follica's target indication.
  • Johnson & Johnson: Consumer health incumbent through Rogaine (minoxidil) and other personal care brands. Comparable as the established consumer hair-growth incumbent Follica would compete against.
  • Eli Lilly: Major pharma whose Olumiant (baricitinib) is approved for severe alopecia areata. Relevant incumbent competitor in the systemic-treatment segment of Follica's market.

Emerging players

  • Cassiopea: Dermatology-focused company that has developed clascoterone (Winlevi) and explored androgenetic alopecia indications. Comparable as a specialty dermatology player with hair-loss relevance.
  • Hims & Hers Health: Digital health company offering hair loss treatments (including finasteride) directly to consumers. Comparable as a direct-to-consumer hair-loss brand, though broader in scope.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

Follica social profiles

Digital presence

Follica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Follica leadership team

Management profile

Number of profiles

Profiles7 records

Follica funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Follica M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Follica

What does Follica do?

Follica develops a regenerative platform technology for hair growth based on a proprietary skin disruption methodology designed to stimulate regenerative hair follicle responses. The company is building both at-home and integrated treatment approaches intended for individuals experiencing hair loss, alopecia, and related conditions, positioning its offering as a non-pharmaceutical alternative to drug-based hair loss therapies.

Is Follica a public or private company?

Follica is a private company. It is classified as venture growth investor backed and is currently operating.

When was Follica founded?

Follica was founded in 2005. It employs 1 to 10 people.

Where is Follica based?

Follica is headquartered in Boston, United States, in the North America region.

Who are Follica's main competitors?

Direct peers on record are Histogen, Keeps, dNovo, Aclaris Therapeutics and Stemson Therapeutics. Broad incumbents are Pfizer, Johnson & Johnson and Eli Lilly. Emerging players are Cassiopea and Hims & Hers Health.

Does Follica have an API?

No public API is recorded for Follica.

What industry is Follica in?

Follica's product category is Regenerative Hair Loss Treatment. Its primary akta.pro industry code is CRABABAE, Treatments & Scalp Care (Serums, Oils, Anti-dandruff, Growth). Its NAICS code is 325411 and its SIC code is 2844.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals